Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MannKind's inhaled insulin product faces US delay

This article was originally published in Scrip

Executive Summary

The US FDA has told MannKind that it will miss the January 16th user fee date for the NDA of its inhaled rapid-acting insulin product Afrezza (formerly Afresa). The drug is awaiting a decision for the treatment of adults with types 1 and 2 diabetes for the control of hyperglycaemia.

Topics

Related Companies

UsernamePublicRestriction

Register

SC006454

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel